Linvoseltamab
Regeneron
['linker-mm1', 'linker,mm,3']
at the ongoing annual meeting 2023, highly anticipated results of the linker-mm1 trial were showcased, leaving a lasting impact on the field of oncology. click here to know more about the key findings from the linker-mm1 trial: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry